5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

Kevin Kotler Biography and Net Worth

Director of BioDelivery Sciences International

Kevin Kotler has served as a member of our Board of Directors since May 2018. Mr. Kotler has over 25 years of experience as an investor and analyst following the healthcare industry. He is the Founder and Managing Member of Broadfin Capital, which is the investment advisor for Broadfin Healthcare Master Fund, Ltd., a healthcare-focused investment fund that he launched in 2005. Mr. Kotler serves as a Director of Avadel Pharmaceuticals since 2018 and as a director of InnerSpace Neuro Solutions, Inc., a privately-held medical device company, since 2014. He served as Director of Novelion Therapeutics Inc., from 2016 to 2018. Mr. Kotler earned a BS in Economics from the Wharton School at the University of Pennsylvania in 1993.

What is Kevin Kotler's net worth?: The estimated net worth of Kevin Kotler is at least $6.14 million as of May 13th, 2021. Mr. Kotler owns 1,098,595 shares of BioDelivery Sciences International stock worth more than $6,141,146 as of April 18th. This net worth approximation does not reflect any other investments that Mr. Kotler may own. Learn More about Kevin Kotler's net worth.
How do I contact Kevin Kotler?: The corporate mailing address for Mr. Kotler and other BioDelivery Sciences International executives is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. BioDelivery Sciences International can also be reached via phone at (919) 582-9050 and via email at [email protected]. Learn More on Kevin Kotler's contact information.
Has Kevin Kotler been buying or selling shares of BioDelivery Sciences International?: Kevin Kotler has not been actively trading shares of BioDelivery Sciences International in the last ninety days. Most recently, on Friday, November 19th, Kevin Kotler bought 100,000 shares of BioDelivery Sciences International stock. The stock was acquired at an average cost of $3.06 per share, with a total value of $306,000.00. Learn More on Kevin Kotler's trading history.
Who are BioDelivery Sciences International's active insiders?: BioDelivery Sciences International's insider roster includes John Golubieski (CFO & Chief Accounting Officer ), Kevin Kotler (Director), Mark Sirgo (Director), and James Vollins (Insider). Learn More on BioDelivery Sciences International's active insiders.

Kevin Kotler Insider Trading History at BioDelivery Sciences International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2021	Buy	100,000	$3.06	$306,000.00
11/5/2021	Buy	257,800	$3.47	$894,566.00
5/13/2021	Buy	50,000	$3.25	$162,500.00	1,098,595
5/11/2021	Buy	150,000	$3.16	$474,000.00	1,098,595

Kevin Kotler Buying and Selling Activity at BioDelivery Sciences International

BioDelivery Sciences International Company Overview

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Today's Range

Now: $5.59

$5.59

$5.60

50 Day Range

MA: $5.58

$5.54

$5.60

2 Week Range

Now: $5.59

$2.50

$5.62

Volume

2,090,567 shs

Average Volume

3,340,554 shs

Market Capitalization

$577.05 million

P/E Ratio

6.74

Dividend Yield

N/A

Beta

0.56

The #1 Crypto for 2024

From InvestorPlace | Ad